The sharpest verdict: Lilly's indirect treatment comparison positions orforglipron 17.2 mg favorably against oral semaglutide 25 mg on both body weight loss (1.5% greater) and A1C reduction (0.3% greater) over 52 weeks, but the entire claim rests on a cross-trial indirect comparison — not a head-to-head Phase 3 RCT — which is a materially lower evidence tier and will not satisfy regulators or HTA bodies as primary comparative evidence. [1] The comparison draws from two separate studies, ACHIEVE-3 (orforglipron) and PIONEER PLUS (oral semaglutide), meaning differences in enrolled populations, background antidiabetic therapies, titration schedules, and trial conduct between the two studies are uncontrolled confounders that the press release does not address. The 1.5% and 0.3% point estimates are presented without confidence intervals or statistical significance thresholds, preventing any assessment of whether these differences are robust or within the noise of cross-trial heterogeneity. On the competitive landscape, oral semaglutide at 25 mg is itself a high-dose formulation exceeding the originally approved 14 mg/day; PIONEER PLUS data confirm that semaglutide 50 mg outperformed 25 mg on both endpoints, a dose not addressed in this ITC. [2][3] The ACHIEVE-3 head-to-head Phase 3 RCT data — the highest evidence tier available — show orforglipron 12 mg and 36 mg were superior to oral semaglutide 7 mg and 14 mg on HbA1c, but also show GI adverse event rates of 58–59% for orforglipron versus 37–45% for semaglutide, and discontinuation due to adverse events approximately double that of semaglutide (9–10% vs. [1] 4–5%). No cardiovascular outcomes data, no pooled safety analysis, and no HTA cost-effectiveness results are present in the available evidence. No closely comparable precedent for a non-peptide small-molecule oral GLP-1 RA approval exists in the retrieved evidence; the oral semaglutide PIONEER program is the nearest structural analogue but is mechanistically distinct at the molecular level. The sharpest risk: the tolerability disadvantage versus oral semaglutide is established at Phase 3 RCT level — the highest evidence tier — while the efficacy advantage is established only at ITC level, the lowest comparative tier.
The 1.5% weight and 0.3% A1C advantages derive from an indirect treatment comparison across ACHIEVE-3 and PIONEER PLUS — not a head-to-head RCT — with no confidence intervals reported; the Phase 3 RCT (ACHIEVE-3) simultaneously shows orforglipron's GI discontinuation rate is approximately double oral semaglutide's.
| Indication | type 2 diabetes |
| Drug | orforglipron |
| Mechanism of Action | GLP-1 receptor agonist |
| Company | Eli Lilly and Company |
| Trial Phase | Phase 3 |
| Trial Acronym | ACHIEVE-3, PIONEER PLUS |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Endocrinology & Metabolic Diseases |
| Comparator Drug | oral semaglutide |
| Meeting Name | 62nd Annual Meeting of the European Association for the Study of Diabetes |
| Meeting Location | Milan, Italy |
| Comparison Duration | 52 weeks |
| Weight Loss Difference | 1.5% |
| Weight Loss Confidence Interval | -2.7% to -0.2% |
| A1C Reduction Difference | 0.3% |
| A1C Reduction Confidence Interval | -0.6% to -0.1% |
| Orforglipron Dosage | 17.2mg |
| Oral Semaglutide Dosage | 25mg |
| Covariate Adjustment | age, gender, baseline A1C, and starting weight |
| Orforglipron Current Approval | US for adults with obesity or overweight who have weight-related health issues |
| Original Discoverer | Chugai Pharmaceutical |
| Licensing Year | 2018 |
| ACHIEVE Program Enrollment | over 6,000 adults |
Lilly's Foundayo Shows Superior Weight and A1C Reduction vs. Oral Semaglutide
Eli Lilly and Company announced findings from an indirect treatment comparison of its investigational therapy orforglipron (Foundayo) against oral semaglutide in adults with type 2 diabetes. The analysis, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes, compared orforglipron 17.2mg with oral semaglutide 25mg over 52 weeks, drawing data from the ACHIEVE-3 and PIONEER PLUS studies. Results indicated that participants on orforglipron experienced a 1.5% greater average body weight loss and a 0.3% greater reduction in A1C levels compared to those on oral semaglutide.
- The indirect treatment comparison revealed that orforglipron led to a statistically significant average body weight loss of 1.5% more than oral semaglutide (95% CI: -2.7% to -0.2%) over 52 weeks. This finding suggests orforglipron's potential as a potent option for weight management in adults with type 2 diabetes, building on its existing approval for obesity.
- Beyond weight reduction, orforglipron also demonstrated superior blood sugar control, achieving a 0.3% greater reduction in A1C levels compared to oral semaglutide (95% CI: -0.6% to -0.1%). This A1C improvement was observed after covariate adjustment for factors like age, gender, baseline A1C, and starting weight, reinforcing the robustness of the glycemic benefit.
- Orforglipron, a once-daily oral GLP-1 receptor agonist, is already approved in the US for adults with obesity or overweight who have weight-related health issues. Its simple administration, free of fasting or water restrictions, combined with the observed A1C and weight-lowering effects, positions it as a potentially foundational therapy for type 2 diabetes management globally, offering a convenient alternative to existing treatments.
Foundayo's Comparative Efficacy Against Oral Semaglutide
Recent clinical evidence across multiple study designs highlights meaningful advances in glycemic control, weight reduction, and cardiometabolic risk management in type 2 diabetes mellitus (T2DM). The studies below span pharmacological, dietary, and digital health interventions, reflecting the breadth of current therapeutic investigation.
| Study Name | Intervention | Key Efficacy Outcomes | Key Safety Outcomes |
|---|---|---|---|
| Low-energy total diet replacement in insulin-treated T2DM (ISRCTN21335883) | Low-energy total diet replacement (TDR) vs. standardized dietetic care | Mean weight loss 9.8 kg (SD 4.9) vs. 5.6 kg (SD 6.1) at 12 months (adjusted mean difference −4.3 kg; 95% CI −6.3 to −2.3; p<0.001); insulin therapy discontinued in 39.4% of TDR completers vs. 5.6% of controls; HbA1c fell by 4.7 mmol/mol (p=0.02); QoL improved by 11.1 points (SD 21.8) vs. 0.71 points (SD 19.4) (8.6 points; 95% CI 2.0 to 15.2; p=0.01) | Described as a safe treatment option; requires maintenance support for long-term success |
| T-emerge 4 Trial | Taspoglutide (10 mg or 20 mg once weekly) vs. sitagliptin (100 mg once daily) vs. placebo, adjunct to metformin | HbA1c reductions at 24 weeks: taspoglutide 10 mg −1.23% (SE 0.06), 20 mg −1.30% (SE 0.06) vs. sitagliptin −0.89% (SE 0.06); weight loss: taspoglutide 10 mg −1.8 kg (0.3), 20 mg −2.6 kg (0.3) vs. sitagliptin −0.9 kg (0.3); effects on HbA1c and weight continued through 52 weeks | No severe hypoglycemia with any active treatment; higher gastrointestinal adverse events, allergic and injection-site reactions in taspoglutide groups; anti-taspoglutide antibodies confirmed in 46% of patients; high discontinuation rates led to discontinuation of dosing |
| Cardiorenal Safety Markers With Injectable GLP-1 Agonists in T2DM (Network Meta-Analysis) | Injectable GLP-1 receptor agonists (efpeglenatide, albiglutide, semaglutide, dulaglutide, liraglutide, others) | Efpeglenatide ranked highest for MACE reduction (OR: 0.74; 95% CI: 0.62–0.87; SUCRA: 81.5%) and renal composite outcomes (OR: 0.68; 95% CI: 0.57–0.81; SUCRA: 81.33%); albiglutide, semaglutide, dulaglutide, and liraglutide also provided significant benefits | No major inconsistency or publication bias detected; 15 randomized trials, pooled sample >90,000 participants |
| Real-World Evidence of Tirzepatide in Indian Adults With T2DM | Tirzepatide (dual GIP/GLP-1 receptor agonist) | Mean HbA1c decreased from 8.7 ± 1.4% to 6.9 ± 1.0% (mean change −1.8 ± 1.2%; p<0.001); 59.2% achieved HbA1c <7% at 3 months; mean body weight declined by 4.7 ± 3.2 kg (5.7%; p<0.001); significant improvements in systolic BP (−5.6 mmHg), total cholesterol (−16.6 mg/dL), LDL-cholesterol (−12.2 mg/dL), HDL-cholesterol (+2.6 mg/dL), triglycerides (−46.4 mg/dL), and FIB-4 index (1.24 ± 0.68 to 1.08 ± 0.54; p=0.004) | Gastrointestinal adverse events in 59.2% of patients, predominantly mild to moderate; treatment discontinuation rate 22.2%, mainly due to gastrointestinal intolerance (36%) and financial constraints (32%) |
| Reversing Type 2 Diabetes — Primary Care-Anchored eHealth Lifestyle Coaching Programme (Denmark RCT) | eHealth lifestyle coaching programme vs. standard care | Mean body weight loss 4.2 kg (95% CI −5.49 to −2.98) vs. 1.5 kg (95% CI −2.57 to −0.48) at 6 months (p=0.005); 39% of intervention patients with elevated baseline HbA1c achieved normalized HbA1c <6.5% vs. 20% in control group (p=0.047) | Not reported |
Addressing Type 2 Diabetes Treatment Limitations with Foundayo
Managing type 2 diabetes remains a complex clinical challenge, with current treatment approaches constrained by issues spanning glycemic durability, safety, and disease progression. Multiple dimensions of therapeutic limitation have been identified across pharmacological strategies, from early monotherapy through insulin intensification.
Beta-cell mass decline and disease progression: A deficit of functional beta-cell mass is an essential factor in the pathophysiology of T2DM. Pancreatic fat accumulation — which increases with obesity — is suggested to cause beta-cell dysfunction, and progressive decline in beta-cell function with disease duration results in worsening glycemic control and treatment failure.
Stepwise escalation and glycemic durability: Stepwise escalation therapy is associated with a progressive decline in beta-cell function and a median time to treatment failure of 36.1 months, compared to 61.9 months with early combination therapy. Stepwise approaches also yield inferior A1C reduction (mean difference of -0.49% in favour of early combination therapy, 95% CI: -0.53 to -0.45, p<0.001).
Clinical inertia in insulin intensification: Among patients treated with GLP-1 receptor agonists in a real-world Italian cohort, 60.3% did not initiate basal insulin or fixed-ratio combination therapy despite inadequate control. HbA1c levels at intensification time of ≥9.0% and suboptimal basal insulin titration were identified as signals of clinical inertia.
Hypoglycemia and weight gain as barriers to intensification: Common patient barriers to insulin intensification include regimen complexity and increased risk of hypoglycemia and weight gain. Whichever intensification strategy is initiated must be tailored to the individual, accounting for overall health status, meal patterns, and hypoglycemia risk.
Cardiovascular and renal risk management: Intensive glycemic control reduces the risk of microvascular complications, but there is less clear evidence for decreasing risk of macrovascular events such as stroke. Vitamin D deficiency was identified as a risk marker for MACE and heart failure in type 1 diabetes and for heart failure in type 2 diabetes, though not for microvascular complications or all-cause mortality, underscoring the multifactorial nature of complication risk beyond glycemic targets alone.
A New Oral GLP-1 RA Challenges Market Leaders
This announcement from Eli Lilly regarding orforglipron's indirect comparison against oral semaglutide marks a significant moment in the evolving landscape of type 2 diabetes and weight management therapies. Orforglipron, an investigational oral small-molecule GLP-1 receptor agonist, demonstrated a 1.5% greater average body weight loss and a 0.3% greater reduction in A1C levels over 52 weeks compared to oral semaglutide. These findings, if confirmed in head-to-head trials, suggest a potentially superior efficacy profile for orforglipron, positioning it as a formidable contender in a highly competitive market.
The strategic implications for Eli Lilly are substantial. The superior efficacy, combined with the convenience of an oral small-molecule formulation, could allow the company to carve out a significant niche, appealing to patients who prefer non-injectable options but still seek potent glycemic control and weight loss. This could intensify competition for existing oral GLP-1 RAs, particularly oral semaglutide, which has established itself as a key player. The market is increasingly valuing both efficacy and patient convenience, and orforglipron appears poised to deliver on both fronts.
However, several critical risks must be carefully considered. Firstly, the data stems from an indirect treatment comparison, which, by its nature, is subject to limitations and potential biases from differences in study designs and patient populations. While informative, these results are not as definitive as those from a direct head-to-head trial. Secondly, like other GLP-1 RAs, orforglipron is associated with dose-dependent gastrointestinal adverse events such as nausea, vomiting, and diarrhea, which can lead to treatment discontinuation. Managing these side effects will be crucial for patient adherence. Finally, while oral semaglutide has established cardiovascular safety data, orforglipron, as an investigational therapy, currently lacks comprehensive long-term cardiovascular outcomes data. This will be a key area of scrutiny for regulatory bodies, prescribers, and payers, as cardiovascular benefits are increasingly a standard expectation for new diabetes therapies. Future research, including direct comparative trials and long-term safety studies, will be essential to fully understand orforglipron's place in therapy.
Frequently Asked Questions
References
- [1] Castelnuovo G, Manzoni GM et al.. TECNOB: study design of a randomized controlled trial of a multidisciplinary telecare intervention for obese patients with type-2 diabetes. BMC public health. 2010 Apr 23. 20416042
- [2] Boustani MA, Pittman I 4th et al.. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years. Diabetes, obesity & metabolism. 2016 Aug. 27161178
- [3] Kreimer F, Schlettert C et al.. The impact of diabetes mellitus on the outcome of troponin-positive patients with non-obstructive coronary arteries. International journal of cardiology. Heart & vasculature. 2024 Feb. 38328690
- [4] Chandra KP, Gupta M et al.. Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits. Cureus. 2026 Feb. 41798487
- [5] Longato E, Di Camillo B et al.. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study. Cardiovascular diabetology. 2021 Nov 13. 34774054
- [6] Bergenstal RM, Forti A et al.. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes therapy : research, treatment and education of diabetes and related disorders. 2012 Dec. 23138449
- [7] Rai A, Kolli M et al.. Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis. Cureus. 2025 Nov. 41367446
- [8] Christensen JR, Laursen DH et al.. Reversing Type 2 Diabetes in a Primary Care-Anchored eHealth Lifestyle Coaching Programme in Denmark: A Randomised Controlled Trial. Nutrients. 2022 Aug 19. 36014930
- [9] Brown A, Dornhorst A et al.. Low-energy total diet replacement intervention in patients with type 2 diabetes mellitus and obesity treated with insulin: a randomized trial. BMJ open diabetes research & care. 2020 Jan. 32049634
- [10] Eisa N, Barood O. Early Combination Therapy vs Stepwise Escalation in Newly Diagnosed Type 2 Diabetes: A Systematic Review and Meta-analysis of Multiple Clinical Outcomes. Canadian journal of diabetes. 2026 Jul. 41707802
- [11] Hoste J, Daci E et al.. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data. Acta clinica Belgica. 2014 Jun. 24820924
- [12] Heerspink HJL, Kosiborod M et al.. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney international. 2018 Jul. 29735306
- [13] Kruger DF. Intensifying insulin treatment: options, practical issues, and the role of the nurse practitioner. Journal of the American Academy of Nurse Practitioners. 2012 Apr. 22564102
- [14] Tougaard NH, Hansen TW et al.. Vitamin D deficiency and development of complications in individuals with type 1 and type 2 diabetes: A cohort study. Journal of diabetes and its complications. 2023 Oct. 37716257
- [15] Kwiendacz H, Nabrdalik K et al.. The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review. Advances in therapy. 2023 Aug. 37326901
- [16] Shimoda M, Osonoi T et al.. Durability and Safety of Imeglimin as an Add-On to DPP-4 Inhibitors in Japanese Type 2 Diabetes: The 104-Week FAMILIAR Trial. Diabetes, obesity & metabolism. 2026 Oct. 42473296
- [17] Candido R, Nicolucci A et al.. Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2023 Nov. 37679243
- [18] Ayvaz G, Keskin L et al.. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study. Current medical research and opinion. 2015 Apr. 25697921
- [19] Moustafa B, Trifan G. The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases. Current neurology and neuroscience reports. 2025 May 24. 40411658
- [20] Inaishi J, Saisho Y. Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review. Nutrients. 2020 Dec 16. 33339276
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
